Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Advanced Therapeutics|December 23, 2024
Evaluation of Bioprinted Autologous Cartilage Grafts in an Immunocompetent Rabbit ModelDavid Gvaramia, Philipp Fisch, Killian Flégeau, et al.
Frontiers in Oncology|February 29, 2024
Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies - a single center studyFrederic Jungbauer, Annette Affolter, Christoph Brochhausen, et al.
BMJ Open|December 22, 2021
Efficiency benchmarks in the surgical management of primary rhegmatogenous retinal detachment: a monocentric register cohort study of operating room time metrics and influential factorsReinhard Angermann, Anna Lena Huber, Markus Hofer, et al.
Cancer Reports (Hoboken, N.J.)|November 11, 2025
Real-World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient-Specific Factors Influencing Survival and Response RateLena Huber, Constanze Kohler, Anne Lammert, et al.
Cancers|July 13, 2024
C-Reactive Protein Kinetic as a Potential Predictive and Prognostic Factor during Treatment with Checkpoint Inhibitors in R/M-HNSCCFrederic Jungbauer, Claudia Scherl, Nicole Rotter, et al.
Acta Ophthalmologica|June 19, 2021
The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48-month follow-up studyReinhard Angermann, Markus Hofer, Anna Lena Huber, et al.
Anticancer Research|July 26, 2024
Influence of Tyrosine Kinase Inhibitors and Everolimus on TGFβ1 and TGF-β Receptor 2 in Squamous Cell Carcinoma CellsLena Huber, Manuel Thomas Knüttel, Benedikt Kramer, et al.
Der Anaesthesist|August 27, 2021
[Professional teamwork and communication in the operating room-A narrative review]Anne Lammert, Markus Alb, Lena Huber, et al.
Anticancer Research|September 29, 2020
FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and EverolimusLena Huber, Richard Birk, Manuel Knuettel, et al.
Retina (Philadelphia, Pa.)|November 3, 2021
CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONReinhard Angermann, Anna Lena Huber, Yvonne Nowosielski, et al.
Pageof 4